Recent News

• 11.03.2026 - Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
• 10.20.2026 - Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
• 09.02.2026 - Zevra Therapeutics to Present at Upcoming Investor Conferences
• 08.25.2026 - Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
• 08.21.2026 - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 08.05.2026 - Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
• 08.04.2026 - Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
• 08.03.2026 - Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
• 07.24.2026 - Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
• 07.22.2026 - Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

Recent Filings

• 11.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2026 - 8-K Current report
• 11.03.2026 - EX-99.1 EX-99.1
• 10.13.2026 - 144 Report of proposed sale of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2026 - 144 Report of proposed sale of securities
• 08.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors